FDA Clearance Tracker · P130004-S011
ReSure Sealant
Last checked: Nov 20, 2026Latest source record: Nov 2, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Nov 2, 2021
Approved
Time to decision
145 days
Received Jun 10, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P130004-S011
- Device name
- ReSure Sealant
- Applicant
- Ocular Therapeutix, Inc.
- Applicant location
- Bedford, MA
- Received
- Jun 10, 2021
- Decided
- Nov 2, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P130004
Device type
- Device type
- Ophthalmic Sealant (PFZ)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for updates to the labeling to include the findings of the Post-Approval Study (PAS) designated as the Retrospective Analysis Study for Endophthalmitis.
Source documents
Other decisions for Ocular Therapeutix, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.